journal article·2026-07Open access

FeSO4-Vitamin C co-loaded active targeting liposome inhibits liver cancer through synergistic ferroptosis mechanism

Hao Yang, Hui Hou, Hong Li, Mengsi Yin, Wei Zhang, Xianglong Wang, Fuyu Zhang, Faxin Zhang, Mingyuan Li, Xiangcheng Wang, Xianggao Zhu

Materials & Design· Volume 267

Abstract

• Vc maintains the stability of Fe 2+ during storage. • High concentrations of Fe 2+ and Vc within cells exert a synergistic effect in amplifying ferroptosis-associated oxidative stress • Fe-Vc-LIP-Gal integrates the passive and active tumor targeting, which can significantly enhance the intracellular delivery efficiency of Fe 2+ and Vc.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Ferroptosis and cancer prognosis · Cancer, Lipids, and Metabolism · Iron Metabolism and Disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (58)

Show source-provided references
1. Recent process in organic small molecular fluorescent probes for tracking markers of tumor redox balance10.1016/j.trac.2023.117461 ↗
2. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 202010.1016/S2213-8587(22)00035-3 ↗
3. Tailoring multifunctional small molecular photosensitizers to in vivo self-assemble with albumin to boost tumor-preferential accumulation, NIR imaging, and photodynamic/photothermal/immunotherapy
4. A molybdenum disulfide nanozyme with charge-enhanced activity for ultrasound-mediated cascade-catalytic tumor ferroptosis10.1002/anie.202301206 ↗
5. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
6. Emerging insights into the role of ferroptosis in the pathogenesis of autoimmune diseases10.3389/fimmu.2023.1120519 ↗
7. Highly selective and effective ferroptosis liposomal nanodrugs for synergistic antitumor therapy10.1016/j.cej.2024.152480 ↗
8. Metabolism-regulated ferroptosis in cancer progression and therapy10.1038/s41419-024-06584-y ↗
9. Ferroptosis at the nexus of metabolism and metabolic diseases10.7150/thno.100080 ↗
10. Role of ferroptosis and ferroptosis-related long non-coding RNA in breast cancer10.1186/s11658-024-00560-2 ↗
11. Ferroptosis: mechanisms, biology and role in disease10.1038/s41580-020-00324-8 ↗
12. Ferroptosis: a flexible constellation of related biochemical mechanisms10.1016/j.molcel.2023.03.005 ↗
13. Efficient NIR-II type-I AIE photosensitizer for mitochondria-targeted photodynamic therapy through synergistic apoptosis-ferroptosis10.1021/acsnano.2c12319 ↗
14. Iron metabolism: state of the art in hypoxic cancer cell biology10.1016/j.abb.2022.109199 ↗
15. Redox modulator iron complexes trigger intrinsic apoptosis pathway in cancer cells10.1016/j.isci.2024.109899 ↗
16. Targeting ferroptosis in renal cell carcinoma: potential mechanisms and novel therapeutics10.1016/j.heliyon.2023.e18504 ↗
17. Recent progress of ferroptosis in cancers and drug discovery
18. Cell signaling pathways based on vitamin C and their application in cancer therapy10.1016/j.biopha.2023.114695 ↗
19. Cancer: a collagen disease, secondary to a nutritional deficiency
20. Therapeutic use of vitamin C in cancer: physiological considerations10.3389/fphar.2020.00211 ↗
21. Polarization of tumor-associated macrophages promoted by vitamin C-loaded liposomes for cancer immunotherapy10.1021/acsnano.2c08446 ↗
22. Metabolic control by dehydroascorbic acid: questions and controversies in cancer cells10.1002/jcp.28637 ↗
23. In vitro and in vivo assessment of high-dose vitamin C against murine tumors10.3892/etm.2016.3707 ↗
24. Endocytosis inhibition in humans to improve responses to ADCC-mediating antibodies10.1016/j.cell.2020.02.019 ↗
25. Nano-formulations of natural antioxidants for the treatment of liver cancer10.3390/biom14081031 ↗
26. Factors affecting the place of death in patients with liver cancer in China, 2013–2020: a population-based study10.1016/j.cpt.2024.04.001 ↗
27. Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma10.1016/j.pscia.2024.100046 ↗
28. Point-of-care testing for early-stage liver cancer diagnosis and personalized medicine: biomarkers, current technologies and perspectives10.1016/j.heliyon.2024.e38444 ↗
29. Association of surgical margin on prognosis after hepatectomy for colorectal cancer liver metastases with RAS mutations
30. Impact of perioperative SARS-CoV-2 omicron infection on postoperative complications in liver cancer hepatectomy: a single-center matched study10.1016/j.ijid.2023.12.002 ↗
31. Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses10.1039/D2CS00757F ↗
32. Redox-regulating nanotherapeutics potentiating ferroptosis-driven cancer treatment10.1016/j.cej.2024.149518 ↗
33. Oxidative stress and the multifaceted roles of ATM in maintaining cellular redox homeostasis10.1016/j.redox.2024.103269 ↗
34. Cyclodextrin-derived ROS-generating nanomedicine with pH-modulated degradability to enhance tumor ferroptosis therapy and chemotherapy
35. NIR-II-responsive versatile nanozyme based on H2O2 cycling and disrupting cellular redox homeostasis for enhanced synergistic cancer therapy10.1021/acsbiomaterials.4c00929 ↗
36. NADPH oxidase-like nanozyme for high-efficiency tumor therapy through increasing glutathione consumption and blocking glutathione regeneration10.1002/adhm.202303309 ↗
37. Stimuli-responsive cancer nanomedicines inhibit glycolysis and impair redox homeostasis10.1016/j.actbio.2023.06.016 ↗
38. Broadening horizons: the role of ferroptosis in cancer10.1038/s41571-020-00462-0 ↗
39. Strategic chemical synthesis and application of nanocarriers responsive to the tumor microenvironment10.1016/j.nantod.2024.102421 ↗
40. Cationic liposomes co-deliver chemotherapeutics and siRNA for the treatment of breast cancer10.1016/j.ejmech.2022.114198 ↗
41. Composition design and medical application of liposomes10.1016/j.ejmech.2019.01.007 ↗
42. F7 and topotecan co-loaded thermosensitive liposome as a nano-drug delivery system for tumor hyperthermia10.1080/10717544.2020.1772409 ↗
43. Galactose: a versatile vector unveiling the potentials in drug delivery, diagnostics, and theranostics10.3390/ph17030308 ↗
44. Advances in nucleic acid therapeutics: structures, delivery systems, and future perspectives in cancer treatment10.1007/s10238-024-01463-4 ↗
45. MRI contrast agents in glycobiology10.3390/molecules27238297 ↗
46. The year in cardiovascular medicine 2021: dyslipidaemia10.1093/eurheartj/ehab875 ↗
47. Asialoglycoprotein receptor (ASGPR): a peculiar target of liver-specific autoimmunity10.1007/s13317-012-0041-4 ↗
48. Formulation of liposomes loading lentisk oil to ameliorate topical delivery, attenuate oxidative stress damage and improve cell migration in scratch assay10.1016/j.biopha.2021.112351 ↗
49. siRNA-loaded selenium nanoparticle modified with hyaluronic acid for enhanced hepatocellular carcinoma therapy
50. GSH-activatable metal-phenolic networks for photothermal-enhanced chemotherapy and chemodynamic therapy10.3390/jfb14090436 ↗
51. Ferroptosis as a form of cell death—medical importance and pharmacological implications10.3390/ph18081183 ↗
52. The microtubule depolymerizing drugs nocodazole and colchicine inhibit the uptake of Listeria monocytogenes by P388D1 macrophages10.1111/j.1574-6968.1998.tb12895.x ↗
53. Effects of (dihydro) cytochalasin B, colchicine, monensin and trifluoperazine on uptake and processing of liposomes by Kupffer cells in culture. Biochimica et Biophysica Acta (BBA)-Molecular
54. Flower-like composite material delivery of co-packaged lenvatinib and bufalin prevents the migration and invasion of cholangiocarcinoma10.3390/nano12122048 ↗
55. Targeting ferroptosis as a potential prevention and treatment strategy for aging-related diseases10.1016/j.phrs.2024.107370 ↗
56. Enhancement of EPR effect for passive tumor targeting: current status and future perspectives10.3390/app15063189 ↗
57. Cytoplasmic TRIM24 promotes colorectal cancer cell proliferation by activating Wnt/β-catenin signaling10.1038/s41467-025-63685-8 ↗
58. Differential PCNA expression between neoplastic and adjacent mucosa as a prognostic marker in colorectal adenoma-carcinoma progression10.21873/anticanres.17790 ↗